Search Results

Retinitis pigmentosa (RP) is a group of hereditary degenerative diseases affecting 1 of 4000 people worldwide

protein-coupled receptors (aGPCRs) are keys of many physiological events and attractive targets for various diseases

fluorescent GPCR ligands "G-protein coupled receptors (GPCRs) have been largely targeted in a wide range of diseases

The mGlu5 receptor is a promising target for the treatment of psychiatric and neurodegenerative diseases

This has implications for everything from dosing frequency  to resistance barriers  in infectious disease

Monash Institute of Pharmaceutical Sciences, exploring how receptors control localised signaling, how disease

Must-read publications:  Emerging targets, signaling dynamics, and acid-sensing receptors in disease.

phases of clinical development, and across multiple therapeutic areas, including Oncology, Infectious Diseases

Receptors: Insights into Potential Therapeutic Opportunities for COVID-19, Heart Failure, and Alzheimer's Disease Reviews, GPCRs, and more Cell-trafficking impairment in disease-associated LPA6 missense mutants and

The mGlu5 receptor is a promising target for the treatment of psychiatric and neurodegenerative diseases

September 2022 "G protein‐coupled receptors (GPCRs) are valuable therapeutic targets for many diseases

September 2022 "G-protein-coupled receptors (GPCRs) are involved in a wide array of physiological and disease

the C5aR1, which has received enormous attention for its role in both acute and chronic inflammatory diseases

using next-generation GRABNE sensors Reviews, GPCRs, and more Advances in GPCRs: Structure, Mechanisms, Disease Therapeutics Secures VLAIO Grant Supporting Drug Discovery & Development In Endocrine And Metabolic Diseases

However, an imbalance in the chemokine system can also contribute to various diseases, such as inflammatory

chronic clinical syndrome characterized by the reduction in cardiac function and still remains the disease

to map receptor localization in defined states (pharmacological stimulation, genetic modification, disease

) ligands and analogues for their pharmacologic activities and potential therapeutic utility toward diseases

Edge GPCR drug discovery is accelerating — across obesity, CNS, oncology, inflammation, and metabolic disease

Cannabinoids have the potential to treat a variety of diseases, including neurological and metabolic

free fatty acid receptors (FFARs), now regarded as targets for therapeutic intervention for metabolic diseases such as liver disease, obesity and diabetes (Wold and Zhou 2018).

Potential Implications for Idiopathic Pulmonary Fibrosis "Idiopathic pulmonary fibrosis (IPF) is a disease

Sosei Heptares’ world-leading StaR® (stabilized receptor) platform to generate novel antibody leads to disease-relevant

receptor type 9 (CCR9) antagonist and previous phase III clinical candidate for the treatment of Crohn's disease

Immunology Germinal Center-Related G Protein-Coupled Receptors in Antibody-Mediated Autoimmune Skin Diseases quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson's disease

optic nerve crush in mice "Glaucoma is an optic neuropathy and is currently one of the most common diseases

While these small protein GPCRs are valuable drug targets linked to serious diseases, many remain undrugged antagonist analogs have demonstrated powerful efficacies across a range of animal models spanning different disease Since many inflammatory diseases are driven by inappropriate recruitment of monocytes into tissues, CCR2 diversified portfolio of GPCR-targeted drug candidates for the treatment of cancer and other serious diseases Journal of Infectious Diseases, 199, 1525-1527. https://doi.org/10.1086/598685 · Demonstration

patient outcomes "Triple-negative breast cancer (TNBC) is a particularly aggressive and heterogeneous disease

Cells: Implications for Targeted Therapy "Pancreatic ductal adenocarcinoma (PDAC) remains an aggressive disease

focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases